USPTO 2015–2025 USPTO PatentsView Foreign Corporation

GeneMind Biosciences Company Limited

USPTO PatentsView assignee record - 19 granted patents across 14 technology areas, recorded in grant years 2019–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr).

RSS updates for this company

The verdict

According to USPTO PatentsView, Genemind ranks #15,310 of 49,997 tracked US assignees by granted-patent volume, with 19 patents across 14 technology areas.

#15,310
of 49,997 US assignees by volume
Top 20%
by Innovation Score (46.9/100)
16.6
avg claims per patent
+300%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R15310 · Foreign Corporation #15,310 · 19 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-MICRO 19 grants
  • MID-PACK #15,310/49,997
  • PHOTO-FINISH Gaodi Digital…
  • CPC-FOCUS C12Q · 14 areas
  • INNOV-PAR 46.9/100
  • CLAIMS-RICH 16.6 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-SURGE +300% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Gaodi Digital (Qingdao) Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Genemind’s 46.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Genemind

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Genemind's Innovation Score is 46.9/100 (top 20% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Genemind?

Each dot is one of Genemind’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Genemind’s own 16.6 claims/patent is at or below the 17.2 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Genemind vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 18.918.91919.1 010203040 Granted patents (volume) Avg claims / patent GSG Holdings, Inc. - 19, 19.21GSG HoldingsGuangzhou Shengwei Electric Manufacturing Co., Ltd. - 19, 2Guangzhou Shengwe…Gaodi Digital (Qingdao) Co., Ltd. - 19, 1.42Gaodi Digital (Qi…Gas Technologies LLC - 19, 17.21GasGenesis Medical Devices LLC - 19, 19.47Genesis Medical D…Georgia-Pacific LLC - 19, 19.63Georgia-pacificGiner, Inc. - 19, 31.37GinerGlobal Circuit Innovations Incorporated - 19, 15.32Global Circuit In…GeneMind Biosciences Company Limited - 19, 16.63Genemind Bioscien…
Genemind vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Genemind's grants concentrate

GeneMind Biosciences Company Limited is a focused PatentsView assignee: 14 CPC subclasses with 52.6% of grants classified under C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr). Peak complete grant year is 2022 (5 grants) versus a trough of 2 in 2021. By volume, Genemind sits between GSG Holdings, Inc. and Global Circuit Innovations Incorporated.

Genemind's three-year grant acceleration

GeneMind Biosciences Company Limited shows 10 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at GeneMind's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows GeneMind holds 19 patents at rank #15,314, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near GeneMind

By rank, the assignees closest to #15,314 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in GeneMind's primary technology class.

Genemind's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

47 Top 20% higher than 80% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

123456 201920212022202320242025 4
USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table
GeneMind Biosciences Company Limited patent grants by year, 2015–2025
Year Patents Granted Share of Period
2019 3 15.8%
2021 2 10.5%
2022 5 26.3%
2023 2 10.5%
2024 3 15.8%
2025partial year 4 21.1%

Which technologies does GeneMind Biosciences Company Limited patent most?

Top 14 of 14 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

GeneMind Biosciences Company Limited's patent record in context - here's where to go next.

  • GeneMind Biosciences Company Limited's lead technology class is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr), 52.6% of its portfolio - see every assignee active in that class. Explore C12Q
  • Ranked #15,310 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare GeneMind Biosciences Company Limited against GSG Holdings, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 46.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.